BSEInsider Trading / SAST2h ago · 25 Sept 2026, 04:20 pm

Closure of Trading Window

Akums Drugs and Pharmaceuticals Ltd · 544222

✦ AI SummaryRegulatory

Akums Drugs and Pharmaceuticals Ltd has announced the closure of its trading window for all designated persons, including their immediate relatives, from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ending September 30, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst3/10
Governance Concern2/10
Regulatory Risk8/10
Balance Sheet Risk4/10
Liquidity Impact6/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Akums Drugs and Pharmaceuticals Ltd - 544222 - Closure of Trading Window

Attachments (1)

📄

85b56aad-5061-4881-a24e-e36ff947321f.pdf

pdf

Download →
View document text
Ref: Akums/Exchange/2026-27/51 September 25, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd BSE Limited Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring, Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy Bandra (E), Mumbai – 400 051 Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 544222 Symbol: AKUMS Sub: Closure of Trading Window Respected Sir/Ma’am, This is to inform you that in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the ''Code of Conduct to Regulate, Monitor and Report Trading by designated persons in securities of the Company'', the trading window for dealing in securities of the Company will be closed for all the designated persons (including their immediate relatives) from 1st October, 2026 and shall remain closed till 48 hrs. after the declaration of un-audited (Standalone & Consolidated) Financial Results of the Company for the quarter ending 30th September, 2026. Further, the date of meeting of the Board of Directors of the Company to consider and approve the un-audited (Standalone & Consolidated) Financial Results of the Company for the aforesaid periods shall be intimated in due course. This is for your information and records. Thanking You For Akums Drugs and Pharmaceuticals Limited Dharamvir Malik Company Secretary & Compliance Officer